Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 8/20 | 0.57 |
| ▸ | RXRG | P48443 | 6/20 | 0.47 |
| ▸ | RXRB | P28702 | 6/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112943 | 0.84 | RXRA (0.63) | RXRARXRGRXRBPTGS1PTGS2 | |
| SCHEMBL29374183 | 0.84 | RXRA (0.63) | RXRARXRGRXRBPTGS1PTGS2 | |
| SCHEMBL3633427 | 0.83 | RXRA (0.65) | RXRARXRGRXRB | |
| SCHEMBL7081379 | 0.78 | RXRA (0.59) | RXRARXRGRXRB | |
| SCHEMBL7081382 | 0.78 | RXRA (0.59) | RXRARXRGRXRB | |
| SCHEMBL7085844 | 0.76 | RXRA (0.60) | RXRARXRGRXRB | |
| SCHEMBL29403030 | 0.75 | RXRA (0.50) | RXRARXRGRXRBPTGS1PTGS2 | |
| SCHEMBL585772 | 0.75 | RXRA (0.50) | RXRARXRGRXRBPTGS1PTGS2 | |
| SCHEMBL8417710 | 0.75 | RXRA (0.56) | RXRARXRGRXRB | |
| SCHEMBL7088008 | 0.74 | RXRA (0.61) | RXRARXRGRXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-06-04 | — | — | US | disclosed |
| WO-2007064553-A2 | THIAZOLE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143413-A1 | Thiazole Derivatives as CXCR3 Receptor Modulators | CXCR3, CXCR1, CX3CR1 | RXRA 292/4885RXRG 237/4885RXRB 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.